孟鲁司特联合沙丁胺醇治疗小儿支气管哮喘的效果及对ET-1、CysLTs水平的影响

目的将孟鲁司特联合沙丁胺醇用于治疗小儿支气管哮喘,观察其临床疗效及其对血浆内皮素-1(ET-1)及半胱氨酰白三烯(CysLTs)水平的影响。方法选取2014年2月至2017年2月于该院就诊的支气管哮喘患儿140例,按照随机数字表法分为对照组(n=70)和研究组(n=70)。对照组患儿给予沙丁胺醇气雾剂吸入治疗;研究组患儿在对照组的基础上给予孟鲁司特钠咀嚼片。2组患儿治疗疗程均为2周,观察2组患儿治疗2周后的临床疗效。比较2组患儿治疗前及治疗2周后的肺功能指标第1秒用力呼气容积占预计值百分比(FEV1%)、清晨峰流速值占正常预计值的百分比(PEFam%)、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)],ET-1和CysLTs水平。观察比较2组患儿治疗期间不良反应的发生率。结果治疗2周后,研究组和对照组的临床总有效率分别为92.86%和81.43%,研究组明显高于对照组(P<0.05)。治疗期间,对照组和研究组患儿不良反应发生率分别为4.29%和7.14%,差异无统计学意义(P>0.05)。治疗前,2组患儿的肺功能指标(FEV1%、PEFam%、FEV1、FVC),ET-1和CysLTs水平比较,差异无统计学意义(P>0.05)。治疗2周后,2组患儿的肺功能指标(FEV1%、PEFam%、FEV1、FVC),ET-1和CysLTs水平均显著改善(P<0.05),且研究组的肺功能指标(FEV1%、PEFam%、FEV1、FVC)明显高于对照组(P<0.05),ET-1和CysLTs水平明显低于对照组(P<0.05)。结论孟鲁司特联合沙丁胺醇治疗小儿支气管哮喘,具有较好的临床疗效,能减轻患儿体内的炎性反应,改善患儿的肺功能,且安全性高。

Effect of Montelukast combined with Salbutamol on bronchial asthma in children and its effect on the level of ET-1 and CysLTs

Objective To observe the clinical effect of Montelukast combined with Salbutamol in the treatment of bronchial asthma in children and its effect on the levels of plasma endothelin-1(ET-1)and cysteinyl leukotriene(CysLTs).Methods From February 2014 to February 2017,140 children with asthma were randomly divided into control group(n=70)and study group(n=70).Children in the control group were given Salbutamol aerosol inhalation treatment,children in the study group were given Montelukast sodium chewing tablets on the basis of the control group.The course of treatment was 2 weeks in both groups,and the clinical effect was observed after 2 weeks.The lung function indexes(FEV1%,PEFam%,FEV1,FVC),ET-1 and CysLTs were compared before and after treatment.The incidence of adverse reactions was observed and compared between the two groups.Results After 2 weeks of treatment,the total clinical effective rates of the study group and the control group were 92.86%and 81.43%,respectively,which were significantly higher in the study group than in the control group(P<0.05).During the treatment,the incidence of adverse reactions in the control group and the study group were 4.29%and 7.14%,respectively,with no significant difference(P>0.05).Before treatment,there was no significant difference in pulmonary function indexes(FEV1%,PEFam%,FEV1,FVC),ET-1 and CysLTs between the two groups(P>0.05).After 2 weeks of treatment,the pulmonary function indexes(FEV1%,PEFam%,FEV1,FVC),ET-1 and CysLTs of the two groups were significantly improved(P<0.05),and the pulmonary function indexes(FEV1%,PEFam%,FEV1,FVC)of the study group were significantly higher than those of the control group(P<0.05),and the levels of ET-1 and CysLTs were significantly lower than those of the control group(P<0.05).Conclusion Montelukast combined with Salbutamol in the treatment of children′s bronchial asthma has a good clinical effect,which can reduce the inflammatory reaction in children′s body,improve children′s lung function,and be of high safety.